A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
Price : $35 *
At a glance
- Drugs Ipafricept (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 17 May 2017 Planned End Date changed from 1 Apr 2017 to 1 May 2017.
- 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.